Triple-negative breast cancer (TNBC) is a subgroup of breast cancers that by definition lack expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2). A diverse group of tumors, TNBC shares some morphologic and molecular features with basal-like breast cancer, a category of breast cancer defined by gene expression profiling. More likely to occur in young women and African Americans, TNBCs may exhibit aggressive behavior and are associated with poor prognosis despite their initial response to conventional chemotherapy. Because hormonal or HER2-targeted therapies are ineffective for these tumors, the main therapeutic option is systemic chemotherapy. Therefore, identification of new targets for therapy is urgently needed for this group.
To review and present recent literature along with our own experience regarding the clinical and morphologic characteristics and the prevalence of androgen receptor (AR) expression in TNBC, and to discuss the potential use of AR as a therapeutic target for AR(+) TNBC.
Data sources are published articles from peer-reviewed journals in PubMed (US National Library of Medicine).
AR is the most commonly expressed hormone receptor among all breast carcinomas, with a prevalence of 25% to 75% among TNBCs. Therefore, we strongly support the routine assessment of AR in TNBC, and preferably in all breast carcinomas.
三阴性乳腺癌（TNBC) 定义为缺乏ER、PR、HER2表达的一组乳腺癌，分子分型上，TNBC与基底样乳腺癌具有一些共同的形态和分子特点。更常见于年轻女性和非洲女性，TNBCs 表现为侵袭性行为，预后不良，尽管初始对传统化疗有反应。由于激素或HER2靶向治疗对这类肿瘤无效，主要的治疗方法为全身化疗。因此，对这组肿瘤急切需要找到治疗的新靶点。
目的与方法：回顾新近发表文献的临床和形态学特点、并结合我们自己经验，探索AR在TNBC的表达情况，探讨使用AR作为治疗 AR(+) TNBC靶点的可能性。
材料与方法：数据来自PubMed (US National Library of Medicine)发表文章。
结果：AR 是所有乳腺癌中最常表达的激素受体，在TNBCs中表达率为25% 到75%。因此，我们强烈支持常规评价TNBC中AR，并且最好用于全部乳腺癌。